Annual EBITDA
-$114.09 M
-$3.25 M-2.93%
31 December 2023
Summary:
Tonix Pharmaceuticals Holding annual earnings before interest, taxes, depreciation & amortization is currently -$114.09 million, with the most recent change of -$3.25 million (-2.93%) on 31 December 2023. During the last 3 years, it has fallen by -$63.60 million (-125.99%). TNXP annual EBITDA is now -540606.16% below its all-time high of -$21.10 thousand, reached on 31 December 2008.TNXP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$13.38 M
+$3.78 M+22.02%
30 September 2024
Summary:
Tonix Pharmaceuticals Holding quarterly earnings before interest, taxes, depreciation & amortization is currently -$13.38 million, with the most recent change of +$3.78 million (+22.02%) on 30 September 2024. Over the past year, it has increased by +$13.55 million (+50.33%). TNXP quarterly EBITDA is now -557233.33% below its all-time high of -$2400.00, reached on 30 June 2010.TNXP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$76.74 M
+$13.55 M+15.01%
30 September 2024
Summary:
Tonix Pharmaceuticals Holding TTM earnings before interest, taxes, depreciation & amortization is currently -$76.74 million, with the most recent change of +$13.55 million (+15.01%) on 30 September 2024. Over the past year, it has increased by +$43.17 million (+36.00%). TNXP TTM EBITDA is now -852555.56% below its all-time high of -$9000.00, reached on 31 March 2008.TNXP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TNXP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.9% | +50.3% | +36.0% |
| 3 y3 years | -126.0% | +27.8% | +3.9% |
| 5 y5 years | -334.3% | -69.6% | -176.9% |
TNXP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -126.0% | at low | at high | +59.5% | at high | +37.3% |
| 5 y | 5 years | -334.3% | at low | -83.5% | +59.5% | -176.9% | +37.3% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +59.5% | <-9999.0% | +37.3% |
Tonix Pharmaceuticals Holding EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.38 M(-22.0%) | -$76.74 M(-15.0%) |
| June 2024 | - | -$17.15 M(-14.8%) | -$90.29 M(-10.8%) |
| Mar 2024 | - | -$20.14 M(-22.7%) | -$101.22 M(-11.3%) |
| Dec 2023 | -$114.09 M(+2.9%) | -$26.07 M(-3.2%) | -$114.09 M(-4.9%) |
| Sept 2023 | - | -$26.93 M(-4.1%) | -$119.91 M(-2.0%) |
| June 2023 | - | -$28.08 M(-14.9%) | -$122.32 M(+4.1%) |
| Mar 2023 | - | -$33.01 M(+3.5%) | -$117.47 M(+6.0%) |
| Dec 2022 | -$110.84 M(+20.1%) | -$31.89 M(+8.7%) | -$110.84 M(+2.3%) |
| Sept 2022 | - | -$29.34 M(+26.3%) | -$108.40 M(+11.1%) |
| June 2022 | - | -$23.23 M(-11.9%) | -$97.58 M(-0.3%) |
| Mar 2022 | - | -$26.37 M(-10.5%) | -$97.91 M(+6.1%) |
| Dec 2021 | -$92.26 M(+82.8%) | -$29.45 M(+59.0%) | -$92.26 M(+15.6%) |
| Sept 2021 | - | -$18.52 M(-21.4%) | -$79.83 M(+8.9%) |
| June 2021 | - | -$23.55 M(+13.6%) | -$73.29 M(+14.7%) |
| Mar 2021 | - | -$20.73 M(+21.8%) | -$63.92 M(+26.6%) |
| Dec 2020 | -$50.48 M(+75.3%) | -$17.02 M(+41.9%) | -$50.48 M(+19.6%) |
| Sept 2020 | - | -$11.99 M(-15.5%) | -$42.20 M(+10.8%) |
| June 2020 | - | -$14.19 M(+94.6%) | -$38.09 M(+27.8%) |
| Mar 2020 | - | -$7.29 M(-16.5%) | -$29.80 M(+3.5%) |
| Dec 2019 | -$28.80 M(+9.6%) | -$8.73 M(+10.7%) | -$28.80 M(+3.9%) |
| Sept 2019 | - | -$7.89 M(+33.7%) | -$27.71 M(+9.3%) |
| June 2019 | - | -$5.90 M(-6.2%) | -$25.35 M(-0.9%) |
| Mar 2019 | - | -$6.29 M(-17.7%) | -$25.58 M(-2.6%) |
| Dec 2018 | -$26.27 M(+23.8%) | -$7.64 M(+38.2%) | -$26.27 M(+8.8%) |
| Sept 2018 | - | -$5.53 M(-9.8%) | -$24.15 M(-1.2%) |
| June 2018 | - | -$6.13 M(-12.1%) | -$24.44 M(+5.7%) |
| Mar 2018 | - | -$6.97 M(+26.3%) | -$23.13 M(+9.0%) |
| Dec 2017 | -$21.22 M(-45.3%) | -$5.52 M(-5.1%) | -$21.22 M(-8.1%) |
| Sept 2017 | - | -$5.82 M(+20.9%) | -$23.10 M(-7.1%) |
| June 2017 | - | -$4.81 M(-5.0%) | -$24.86 M(-16.8%) |
| Mar 2017 | - | -$5.07 M(-31.6%) | -$29.87 M(-22.9%) |
| Dec 2016 | -$38.76 M | -$7.41 M(-2.2%) | -$38.76 M(-13.3%) |
| Sept 2016 | - | -$7.58 M(-22.9%) | -$44.69 M(-11.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$9.83 M(-29.6%) | -$50.35 M(-3.7%) |
| Mar 2016 | - | -$13.96 M(+4.7%) | -$52.28 M(+8.9%) |
| Dec 2015 | -$48.00 M(+73.8%) | -$13.33 M(+0.7%) | -$48.00 M(+10.0%) |
| Sept 2015 | - | -$13.23 M(+12.5%) | -$43.65 M(+15.3%) |
| June 2015 | - | -$11.76 M(+21.6%) | -$37.85 M(+17.8%) |
| Mar 2015 | - | -$9.67 M(+7.7%) | -$32.13 M(+16.3%) |
| Dec 2014 | -$27.62 M(+154.1%) | -$8.98 M(+20.9%) | -$27.62 M(+23.6%) |
| Sept 2014 | - | -$7.43 M(+22.9%) | -$22.34 M(+24.1%) |
| June 2014 | - | -$6.04 M(+17.0%) | -$18.00 M(+28.2%) |
| Mar 2014 | - | -$5.17 M(+39.4%) | -$14.04 M(+29.1%) |
| Dec 2013 | -$10.87 M(+39.0%) | -$3.70 M(+19.9%) | -$10.87 M(+19.7%) |
| Sept 2013 | - | -$3.09 M(+48.3%) | -$9.08 M(+17.6%) |
| June 2013 | - | -$2.08 M(+4.3%) | -$7.72 M(+3.1%) |
| Mar 2013 | - | -$2.00 M(+4.4%) | -$7.49 M(+13.4%) |
| Dec 2012 | -$7.82 M(+132.2%) | -$1.91 M(+10.5%) | -$6.60 M(+6.8%) |
| Sept 2012 | - | -$1.73 M(-6.3%) | -$6.18 M(+13.1%) |
| June 2012 | - | -$1.85 M(+66.3%) | -$5.46 M(+37.6%) |
| Mar 2012 | - | -$1.11 M(-25.5%) | -$3.97 M(+17.8%) |
| Dec 2011 | -$3.37 M(+75.0%) | -$1.49 M(+47.4%) | -$3.37 M(-11.2%) |
| Sept 2011 | - | -$1.01 M(+186.3%) | -$3.79 M(+36.2%) |
| June 2011 | - | -$353.50 K(-30.9%) | -$2.79 M(+14.4%) |
| Mar 2011 | - | -$511.40 K(-73.3%) | -$2.43 M(+26.2%) |
| Dec 2010 | -$1.92 M(+6129.1%) | -$1.92 M(>+9900.0%) | -$1.93 M(>+9900.0%) |
| Sept 2010 | - | -$3700.00(+54.2%) | -$15.40 K(+7.7%) |
| June 2010 | - | -$2400.00(-58.6%) | -$14.30 K(-44.6%) |
| Mar 2010 | - | -$5800.00(+65.7%) | -$25.80 K(-16.5%) |
| Dec 2009 | -$30.90 K(+46.4%) | -$3500.00(+34.6%) | -$30.90 K(+1.3%) |
| Sept 2009 | - | -$2600.00(-81.3%) | -$30.50 K(-3.5%) |
| June 2009 | - | -$13.90 K(+27.5%) | -$31.60 K(+37.4%) |
| Mar 2009 | - | -$10.90 K(+251.6%) | -$23.00 K(+9.0%) |
| Dec 2008 | -$21.10 K | -$3100.00(-16.2%) | -$21.10 K(+17.2%) |
| Sept 2008 | - | -$3700.00(-30.2%) | -$18.00 K(+25.9%) |
| June 2008 | - | -$5300.00(-41.1%) | -$14.30 K(+58.9%) |
| Mar 2008 | - | -$9000.00 | -$9000.00 |
FAQ
- What is Tonix Pharmaceuticals Holding annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding annual EBITDA year-on-year change?
- What is Tonix Pharmaceuticals Holding quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding quarterly EBITDA year-on-year change?
- What is Tonix Pharmaceuticals Holding TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding TTM EBITDA year-on-year change?
What is Tonix Pharmaceuticals Holding annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TNXP is -$114.09 M
What is the all time high annual EBITDA for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high annual earnings before interest, taxes, depreciation & amortization is -$21.10 K
What is Tonix Pharmaceuticals Holding annual EBITDA year-on-year change?
Over the past year, TNXP annual earnings before interest, taxes, depreciation & amortization has changed by -$3.25 M (-2.93%)
What is Tonix Pharmaceuticals Holding quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TNXP is -$13.38 M
What is the all time high quarterly EBITDA for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2400.00
What is Tonix Pharmaceuticals Holding quarterly EBITDA year-on-year change?
Over the past year, TNXP quarterly earnings before interest, taxes, depreciation & amortization has changed by +$13.55 M (+50.33%)
What is Tonix Pharmaceuticals Holding TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TNXP is -$76.74 M
What is the all time high TTM EBITDA for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high TTM earnings before interest, taxes, depreciation & amortization is -$9000.00
What is Tonix Pharmaceuticals Holding TTM EBITDA year-on-year change?
Over the past year, TNXP TTM earnings before interest, taxes, depreciation & amortization has changed by +$43.17 M (+36.00%)